"I don't think going public is a decisive factor in a company's growth. There are as many risks as market opportunities for listed companies. We should be objective to the pros and cons of capital market," Alphamab chairman Xu Ting said.

The SIP-based biopharmaceutical company has seen a fast growth in recent years, with a list of breakthrough drugs undergoing clinical tests and expected to greatly promote human health.

In his speech, Xu called on a dialectic and rational view on the capital market to avoid possible negative impacts caused by blind pursuit for business expansion.